Competition & Peer Data API & CSV Delivery

Flexion Therapeutics Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Flexion Therapeutics Inc (FLXN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2021
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
-9.88 %
Q3 2021
Net Margin
-142.14 %
Q3 2021

Key Findings: Flexion Therapeutics Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 100M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-15.0% annualized vs trailing 12 months).
  • Peer revenue share: Flexion Therapeutics Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

FLXN Sales vs. its Competitors, Q3 2021

Flexion Therapeutics Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/FLXN/competitors
https://api.csimarket.com/api/v1/companies/FLXN/relationships
https://api.csimarket.com/api/v1/companies/FLXN/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -9.9% for Flexion Therapeutics Inc. Flexion Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Flexion Therapeutics Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Flexion Therapeutics Inc No Yes Yes No
Similar Growth & Profitability (8) 0.00 % (0 of 8) 87.50 % (7 of 8) 62.50 % (5 of 8) 37.50 % (3 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q3 2021

100%market share
  • Flexion Therapeutics Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Flexion Therapeutics Inc and its 0 tracked competitors.

See Flexion Therapeutics Inc's full market share breakdown »

FLXN Stock Performance relative to its Competitors

FLXN Competitors (weighted) Percent change over the selected range

FLXN Stock Performance relative to Similar Growth & Profitability Competitors

FLXN Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range